PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
² Arizona Oncology (US Oncology Network), University of Arizona and Creighton University Phoenix, Phoenix, AZ, USA.

Free article

Editorial

U A Matulonis et al. Ann Oncol. 2017.

Free article

. 2017 Mar 1;28(3):443-447.

doi: 10.1093/annonc/mdw697.

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
² Arizona Oncology (US Oncology Network), University of Arizona and Creighton University Phoenix, Phoenix, AZ, USA.

No abstract available

Comment on

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, Mannel RS, Bell-McGuinn KM, Di Silvestro PA, Jelovac D, Carter JS, Duan W, Resnick KE, Dizon DS, Aghajanian C, Fracasso PM. Thaker PH, et al. Ann Oncol. 2017 Mar 1;28(3):505-511. doi: 10.1093/annonc/mdw635. Ann Oncol. 2017. PMID: 27998970 Free PMC article. Clinical Trial.